RA

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Retrieved on: 
Tuesday, June 13, 2023

WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (RA). Aclaris expects to announce top-line efficacy, safety and other preliminary data from this trial in the fourth quarter of this year.

Key Points: 
  • WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (RA).
  • Aclaris expects to announce top-line efficacy, safety and other preliminary data from this trial in the fourth quarter of this year.
  • The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
  • Secondary efficacy endpoints include ACR50 response, ACR70 response, DAS28-CRP and other pertinent RA measures.

HED Receives National Recognition for Exemplary Engineering Achievement at ACEC's Engineering Excellence Awards

Retrieved on: 
Wednesday, June 14, 2023

ROYAL OAK, Mich., June 14, 2023 /PRNewswire/ -- HED , a national architecture, engineering, and planning firm committed to integrated architectural and engineering design, is proud to announce that it has been honored with a National Recognition Award for exemplary engineering achievement in the 56th annual Engineering Excellence Awards (EEA) by the American Council of Engineering Companies (ACEC).

Key Points: 
  • ROYAL OAK, Mich., June 14, 2023 /PRNewswire/ -- HED , a national architecture, engineering, and planning firm committed to integrated architectural and engineering design, is proud to announce that it has been honored with a National Recognition Award for exemplary engineering achievement in the 56th annual Engineering Excellence Awards (EEA) by the American Council of Engineering Companies (ACEC).
  • The ACEC Engineering Excellence Awards are among the most prestigious honors in the engineering industry, recognizing firms that demonstrate exceptional innovation, technical expertise, and engineering excellence.
  • "We are honored to receive this National Recognition Award from the American Council of Engineering Companies," said Michael Cooper, PE, LEED AP, MBA, FACEC, President of HED.
  • HED's achievement will be celebrated at the ACEC Engineering Excellence Awards Gala on June 13th in Washington, DC.

Corteva Agriscience Announces Availability of PowerCore® Enlist® Refuge Advanced® Corn

Retrieved on: 
Tuesday, June 6, 2023

INDIANAPOLIS, June 6, 2023 /PRNewswire/ -- Corteva Agriscience (NYSE: CTVA) today announced PowerCore® Enlist® Refuge Advanced® (RA) corn will be available for planting in the 2024 growing season in the U.S. and Canada. Farmers will have the added flexibility of integrated refuge, along with an advanced combination of above-ground pest control, herbicide tolerance and industry-leading genetics with PowerCore Enlist RA corn.1

Key Points: 
  • INDIANAPOLIS, June 6, 2023 /PRNewswire/ -- Corteva Agriscience (NYSE: CTVA) today announced PowerCore® Enlist® Refuge Advanced® (RA) corn will be available for planting in the 2024 growing season in the U.S. and Canada.
  • PowerCore Enlist RA corn will be available in a diverse lineup of genetics across a wide range of maturities.
  • Like all products developed through Corteva's R&D programs, the PowerCore Enlist RA corn must pass through rigorous evaluation in several testing locations.
  • Learn more about PowerCore Enlist RA corn: U.S., https://corteva.us/powercoreenlistRA ; and Canada, powercore.corteva.ca and powercore.corteva.ca/fr .

Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit

Retrieved on: 
Monday, June 5, 2023

“This compelling data shows that ‘1805 enhances CD69+ and CD39+ Tregs in human tissue afflicted with IBD and improves anti-inflammatory gene transcription.

Key Points: 
  • “This compelling data shows that ‘1805 enhances CD69+ and CD39+ Tregs in human tissue afflicted with IBD and improves anti-inflammatory gene transcription.
  • This further illustrates ‘1805 unique mechanism of action as it resets the immune system to restore immune system balance,” said Jonathan Rigby, Chief Executive Officer of Revolo.
  • “Additional data for ‘1805 in immune cells harvested from patients with RA showcases the selective alteration of RA cell transcripts compared to controls.
  • When CD69 binds to its ligands, the JAK/STAT5 pathway is activated to promote Treg differentiation and prevent pro-inflammatory Th1/Th7 cell generation.

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Retrieved on: 
Wednesday, May 31, 2023

The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.

Key Points: 
  • The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.
  • “Over the last two decades, CD20 has become well-established as a therapeutic target in multiple autoimmune diseases.
  • In preclinical in vivo studies, imvotamab has demonstrated deep B cell depletion within tissues, where depletion of pathogenic immune cells may be critical to long-term clinical benefit in autoimmune diseases.
  • Imvotamab has also demonstrated in preclinical in vitro studies that it can be more effective in depleting B cells with low levels of CD20 expression as compared to rituximab.

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Retrieved on: 
Tuesday, May 30, 2023

ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.

Key Points: 
  • Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue
    ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue.
  • The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”
    Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).

Skyfactor Announces Winners for 2023 Assessment & Impact Awards in Housing and Residence Life

Retrieved on: 
Wednesday, May 31, 2023

“By harnessing the power of data, colleges gain invaluable insights into students' needs, preferences, and challenges, which helps to create tailored experiences that truly make a difference for students -- especially those in their first year of college. For the fifth year, we’re proud to recognize colleges that are using surveys and data to create a transformative experience for students that helps them feel supported and engaged in campus life,” said Steven Ray, Vice President of Enterprise Solutions for Macmillan Learning.

Key Points: 
  • To recognize the impact that data-driven programs have in supporting on-campus living, Skyfactor Benchworks, a Macmillan Learning company, has named the 2023 Assessment and Impact Awards for Housing and Residence Life.
  • The 2023 Assessment & Impact Awards in Housing and Residence Life winners are:
    Lafayette College was recognized for significant improvement in survey scores related to student staff and creating a sense of community.
  • The Assessment and Impact Awards for Residence Life recognizes colleges that demonstrate intentionality in using insights from data to improve their residence life programs.
  • Skyfactor also has an Assessment and Impact Award for nursing education programs ; winners will be announced this summer.

First Ever Study of RA Patient Attitudes on Bloodwork to Predict Future Treatment Presented by CreakyJoints

Retrieved on: 
Wednesday, May 31, 2023

Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).

Key Points: 
  • Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).
  • Most feared (91.4%) that their current RA medication would stop working and that they would waste time trying to find (81.7%) an alternative, effective therapy.
  • “This study demonstrates that patients understand the value of bloodwork, even when they may not fully comprehend how to interpret results and apply them to decisions about care and treatment.
  • Moreover, people living with RA worry about the trial and error process of RA treatment, especially if it means wasting time on a new medication that doesn’t work for them.

Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

Retrieved on: 
Thursday, May 25, 2023

BERKELEY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced a $150 million oversubscribed and up-sized Series E financing. The financing was led by Deep Track Capital. The syndicate also included new investors 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, TCGX, Venrock Healthcare Capital Partners and existing investors RA Capital Management, The Column Group and Willett Advisors. The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.

Key Points: 
  • The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.
  • “With three clinical-stage candidates currently in development, this financing enables us to continue to advance clinical trials that will yield key data readouts this year and through 2024."
  • Results from the multiple ascending dose cohorts will be presented at the 83rd American Diabetes Association Scientific Sessions.
  • By making subtle improvements in molecular design, Carmot may be able to achieve clinically relevant tolerability and efficacy benefits.

BigCommerce Announces Leadership Changes

Retrieved on: 
Wednesday, May 24, 2023

BigCommerce also announced the addition of Hubert Ban as the company’s Chief Accounting Officer, replacing Vice President of Accounting and Principal Accounting Officer Thomas Aylor, who left BigCommerce May 19.

Key Points: 
  • BigCommerce also announced the addition of Hubert Ban as the company’s Chief Accounting Officer, replacing Vice President of Accounting and Principal Accounting Officer Thomas Aylor, who left BigCommerce May 19.
  • “On behalf of everyone at BigCommerce, I want to thank RA, Jeff and Thomas for their leadership and enormous contributions to BigCommerce over many years and congratulate Daniel, Chuck and Hubert on their new roles,” said BigCommerce CEO Brent Bellm.
  • More than anyone else, RA deserves credit for building BigCommerce from an early-stage startup into a successful public company.
  • Cassidy’s promotion to General Counsel follows nearly six years at BigCommerce, most recently as Vice President and Associate General Counsel.